Merck Cuts 2025 Outlook on Tariffs, Charges
In This Article:
Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 adjusted earnings projection, partly to account for recently imposed tariffs.